Bill Miller
Miller Value Partners
Bill Miller Teva Pharma Industries Ltd ADR stake
total: 460
Miller Value Partners TEVA trades
- Total transactions:
- 28
- New positions:
- 1
- Sold out:
- 1
- Added:
- 12
- Reduced:
- 14
- Held since:
- 2017 Q4
- Held for:
- 29 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q1 report, Bill Miller doesn't hold any Teva Pharma Industries Ltd ADR (TEVA) shares. To date, the estimated cost basis is nearly $12.64 for "buy" trades and estimated average "sell" price is $8.67. Miller Value Partners first purchased TEVA in 2017 Q4, initially acquiring 516,112 shares. Since the initial investment in Teva Pharma Industries Ltd ADR (TEVA), Miller Value Partners has made 27 more transactions.
When did Bill Miller sell Teva Pharma Industries Ltd ADR (TEVA)?
Bill Miller sold off the entire Teva Pharma Industries Ltd ADR (TEVA) position in 2025 Q1.
When did Bill Miller buy Teva Pharma Industries Ltd ADR (TEVA)?
Bill Miller first invested in Teva Pharma Industries Ltd ADR (TEVA) in 2017 Q4 at the reported quarter-end price of $18.95 per share.
What's the cost basis of Miller Value Partners's TEVA stake?
The estimated cost basis for Teva Pharma Industries Ltd ADR (TEVA) stake is around $12.64 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $12.64
- Weighted AVG sell price:
- $8.67
Bill Miller's historical trades in Teva Pharma Industries Ltd ADR
28 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$22.04
|
|
-100% (-10,950)
|
-0.1%
|
|
2024 Q2
|
0.11%
|
10,950
|
$16.25
|
$177,937
|
-5.60% (-650)
|
-0.01%
|
|
2024 Q1
|
0.10%
|
11,600
|
$14.11
|
$163,676
|
-13.43% (-1,800)
|
-0.02%
|
|
2023 Q4
|
0.08%
|
13,400
|
$10.44
|
$139,896
|
-5.80% (-825)
|
-0.01%
|
|
2023 Q3
|
0.09%
|
14,225
|
$10.20
|
$145,095
|
-82.68% (-67,912)
|
-0.46%
|
|
2023 Q2
|
0.41%
|
82,137
|
$7.53
|
$618,492
|
-97.91% (-3,847,647)
|
-1.81%
|
|
2023 Q1
|
2.17%
|
3,929,784
|
$8.85
|
$34,778,588
|
-23.65% (-1,217,243)
|
-0.7%
|
|
2022 Q4
|
3.03%
|
5,147,027
|
$9.12
|
$46,940,886
|
-44.39% (-4,107,848)
|
-2.28%
|
|
2022 Q3
|
4.54%
|
9,254,875
|
$8.07
|
$74,687,000
|
-0.85% (-79,715)
|
-0.04%
|
|
2022 Q2
|
3.93%
|
9,334,590
|
$7.52
|
$70,196,000
|
-7.20% (-724,149)
|
-0.21%
|
|
2022 Q1
|
3.58%
|
$9.39
|
+4.13% (+399,220)
|
|||
|
2021 Q4
|
2.74%
|
$8.01
|
-0.91% (-88,610)
|
|||
|
2021 Q3
|
3.23%
|
$9.74
|
-10.86% (-1,187,654)
|
|||
|
2021 Q2
|
2.82%
|
$9.90
|
+3.62% (+381,718)
|
|||
|
2021 Q1
|
3.46%
|
$11.54
|
+47.82% (+3,414,365)
|
|||
|
2020 Q4
|
2.33%
|
$9.65
|
-11.79% (-953,998)
|
|||
|
2020 Q3
|
2.89%
|
$9.01
|
+3.10% (+243,226)
|
|||
|
2020 Q2
|
4.30%
|
$12.33
|
-0.86% (-67,890)
|
|||
|
2020 Q1
|
4.57%
|
$8.98
|
-19.48% (-1,915,705)
|
|||
|
2019 Q4
|
3.44%
|
$9.80
|
+15.82% (+1,342,915)
|
|||
|
2019 Q3
|
2.36%
|
$6.88
|
+30.63% (+1,990,900)
|
|||
|
2019 Q2
|
2.40%
|
$9.23
|
+43.10% (+1,957,720)
|
|||
|
2019 Q1
|
2.83%
|
$15.68
|
+16.12% (+630,730)
|
|||
|
2018 Q4
|
2.75%
|
$15.42
|
+0.16% (+6,350)
|
|||
|
2018 Q3
|
2.74%
|
$21.54
|
+50.87% (+1,316,840)
|
|||
|
2018 Q2
|
2.37%
|
$24.32
|
+17.93% (+393,640)
|
|||
|
2018 Q1
|
1.61%
|
$17.09
|
+325.29% (+1,678,860)
|
|||
|
2017 Q4
|
0.42%
|
$18.95
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.